Efficacy and safety of recombinant human brain natriuretic peptite in treatment of acute left heart failure

Cao Donglai; Han Leng; Ni Jie

doi:10.3760/cma.j.issn.1673-4777.2014.12.004

Abstract：Objective To investigate the efficacy and safety of recombinant human brain natriuretic peptite(rhBNP) on acute left heart failure.Methods Sixty-five patients with acute left heart failure selected from January 2010 to June 2012 were divided into control group (40 cases) and treatment group (25 cases).According to the random number,the two groups were given basic standard treatment and treatment group was added with rhBNP.The clinical symptoms of two groups of patients with remission,endogenous plasma N-terminal pro-B-type natriuretic peptide(NT-proBNP) level,hemodynamic changes and adverse event were observed.Results After 4 d and 1 week of treatment,the NT-proBNP levels in treatment group were significantly lower than those in the control group; the difference was statistically significant[(5 472 ± 422)μg/L,(3 892 ± 225)μg/L vs (7 627 ± 276) μg/L,(5 983 ± 399)μg/L,P ＜ 0.05].After 1 week of treatment,the effective rate of control group[60％ (24/40)] was lower than that in the treatment group[84％ (21/25)],the difference was statistically significant (x2 =13.29,P =0.024).After 4 d and 1 week of treatment,the left ventricular ejection fraction of treatment group was higher than that in the control group [(45.9 ± 5.9) ％,(52.2 ± 6.2) ％ vs (35.9 ± 3.8) ％,(40.1 ± 3.2) ％] ; the central venous pressure of treatment group was lower than that in the control group; the difference was statistically significant[(8.8 ± 1.9),(6.6 ± 1.2) cmH2O vs (11.4 ± 2.0),(9.3 ± 2.1) cmH2O,P ＜0.05].After 1 year of follow-up,the incidence rate of adverse reaction in control group[37.5％ (11/40)] was higher than that in the treatment group[20％ (4/25)] ; the difference was statistically significant(x2 =11.20,P=0.029).Conclusion rhBNP can effectively improve the cardiac function in patients with heart failure and reduce the incidence of adverse events.